SynthesisAnnals of the Royal College of Surgeons of England2023
Breast cancer liver metastases: systematic review and time to event meta-analysis with comparison between available treatments.
Synthesis in Annals of the Royal College of Surgeons of England, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Article
- Impact of breast cancer characteristics on the development and time to liver metastases: population-based study.BJS open · 2026Article
- Clinical Characteristics and Prognostic Risk Factors in Breast Cancer With Liver Metastasis.The breast journal · 2026Article
- Yttrium-90 for the treatment of breast cancer liver metastases: a global propensity-matched study.Proceedings (Baylor University. Medical Center) · 2026Article
- Histotripsy for multifocal breast cancer liver metastases with early complete metabolic response: a case report.Frontiers in oncology · 2026Article
- Liver Resection after Disease Control with Abemaciclib for Solitary Liver Metastasis from Breast Cancer: A Case Report.Surgical case reports · 2026Article
- Clinical Efficacy of Percutaneous Image-Guided Ablation in Breast Cancer Metastases to the Liver.Cancers · 2025Article
- Utility of liver resection for breast cancer liver metastases, time for action.Hepatobiliary surgery and nutrition · 2022Article
- Echo-guided Local Ablation for Liver Metastasis (Taiwan Academy of Tumor Ablation Guideline).Journal of medical ultrasoundArticle
- Does Hepatic Metastasectomy for Breast Cancer Oligo-Metastasis to the Liver Offer Survival Advantage? Systematic Review and Meta-Analysis.Journal of the West African College of SurgeonsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe current gold standard treatment for breast cancer liver metastases (BCLM) is systemic chemotherapy and/or hormonal therapy. Nonetheless, greater consideration has been given to local therapeutic strategies in recent years. We sought to compare survival outcomes for available systemic and local treatments for BCLM, specifically surgical resection and radiofrequency ablation.
methodsA review of the PubMed (MEDLINE), Embase and Cochrane Library databases was conducted. Data from included studies were extracted and subjected to time-to-event data synthesis, algorithmically reconstructing individual patient-level data from published Kaplan-Meier survival curves.
findingsA total of 54 studies were included, comprising data for 5,430 patients (surgery,
conclusionLocal therapeutic interventions such as liver resection and radiofrequency ablation are effective treatments for BCLM, particularly in patients with metastatic disease localised to the liver. Although the data from this review support surgical resection for BCLM, further prospective studies for managing oligometastatic breast cancer disease are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.